FDA grants Fast Track Designation

Published 

November 17, 2026

November 4, 2026

The development of AKI-007 has been granted a Fast Track Designation for the development of treatment against CRPS pain.

AKIGAI continues its rapid advancement this autumn: IND, Phase 2b/3, financing and now the Fast Track Designation granted by the FDA. We stay humbled, motivated and on course. The trial starts in Q1_2027 at eight US sites.

Dear patients, the trial sites will be announced shortly.